# OnCo record tnbc-metastatic (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc-metastatic/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc-metastatic" ;
  schema:name "Metastatic triple-negative breast cancer"@en ;
  schema:alternateName "Advanced triple-negative breast cancer"@en, "Stage IV TNBC"@en, "Recurrent triple-negative breast cancer"@en ;
  schema:description "Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."@en ;
  schema:url <https://onco.cc/cancers/tnbc-metastatic/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2028485>, <https://doi.org/10.1056/NEJMoa2202809>, <https://doi.org/10.1056/NEJMoa1706450> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/trials/bl-b01d1-307/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/izabright-breast01/>, <https://onco.cc/technologies/trop2-pet/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/technologies/dual-payload-adc/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/terms/cps/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/trials/ascent/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/brain-metastases/> .